These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 4418393)

  • 21. Advertising by physicians (Federal Trade Commission attacks principles of medical ethics).
    Huff JW
    J Med Assoc Ga; 1976 May; 65(5):163-4. PubMed ID: 932583
    [No Abstract]   [Full Text] [Related]  

  • 22. Concerning the case of United States v. American Pharmaceutical Association and Michigan State Pharmaceutical Association, Civil No. G75-558 CA5, W.D. Michigan.
    Am Pharm; 1982 Aug; NS22(8):49-51. PubMed ID: 7124620
    [No Abstract]   [Full Text] [Related]  

  • 23. Medicine and the pharmaceutical industry: what's right, what's wrong, and what's to come.
    Tan SY
    Singapore Med J; 1998 Mar; 39(3):91-5. PubMed ID: 9632964
    [No Abstract]   [Full Text] [Related]  

  • 24. [Study on the availability and cost of medicines in the private sector in Mali].
    Maïga MD; Diawara A
    Med Trop (Mars); 2006 Dec; 66(6):565-8. PubMed ID: 17286022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exploring generic drug use behavior: the role of prescribers and pharmacists in the opportunity for generic drug use and generic substitution.
    Mott DA; Cline RR
    Med Care; 2002 Aug; 40(8):662-74. PubMed ID: 12187180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. State and federal government mandates are changing the face of pharmacy management.
    Giaquinta D
    Manag Care Interface; 2001 May; 14(5):50-2. PubMed ID: 11385948
    [No Abstract]   [Full Text] [Related]  

  • 27. Marketing drugs: debating the real cost. Concern about close ties between doctors and pharmaceutical firms are prompting new financial disclosure laws and education efforts.
    Brand R
    State Legis; 2008 Sep; 34(8):26-9. PubMed ID: 18754159
    [No Abstract]   [Full Text] [Related]  

  • 28. Trends in manufacturer prices of brand name prescription drugs used by older Americans--first quarter 2004 update.
    Gross DJ; Schondelmeyer SW; Raetzman SO
    Issue Brief (Public Policy Inst (Am Assoc Retired Pers)); 2004 Jun; (IB69):1-12, 1-2. PubMed ID: 15368653
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Managed care cost containment involving prescription drugs. American Medical Association, Council on Ethical and Judicial Affairs.
    Food Drug Law J; 1998; 53(1):25-34. PubMed ID: 11795334
    [No Abstract]   [Full Text] [Related]  

  • 30. FTC investigates ADA.
    Freistadt M
    Contact Point; 1988; 66(2):12-5. PubMed ID: 3191695
    [No Abstract]   [Full Text] [Related]  

  • 31. Letter: Posting drug prices.
    Brueggeman JL
    N Engl J Med; 1976 Jul; 295(1):55. PubMed ID: 1272298
    [No Abstract]   [Full Text] [Related]  

  • 32. RX for nosebleed prices.
    Greenwald J
    Time; 2001 May; 157(20):42-3. PubMed ID: 11383109
    [No Abstract]   [Full Text] [Related]  

  • 33. Direct-to-consumer advertising affects provider / patient relationship.
    Contracept Technol Update; 1998 Dec; 19(12):153-5. PubMed ID: 12321805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Confidentiality of prescription drug information in the era of computers and managed care.
    Lo B
    Indiana Law Rev; 2000; 33(3):937-55. PubMed ID: 12449955
    [No Abstract]   [Full Text] [Related]  

  • 35. The Industries Assistance Commission draft report on pharmaceutical products.
    Med J Aust; 1986 Mar; 144(5):253-63. PubMed ID: 3587097
    [No Abstract]   [Full Text] [Related]  

  • 36. ASHP's position on direct-to-consumer advertising of prescription drug products.
    Pierpaoli PG
    Am J Hosp Pharm; 1986 Jul; 43(7):1763-5. PubMed ID: 3752120
    [No Abstract]   [Full Text] [Related]  

  • 37. American pharmaceutical prices.
    Alagona P
    Pharos Alpha Omega Alpha Honor Med Soc; 2002; 65(4):58. PubMed ID: 12592980
    [No Abstract]   [Full Text] [Related]  

  • 38. Should drug prices be negotiated under part D of Medicare? And if so, how?
    Frank RG; Newhouse JP
    Health Aff (Millwood); 2008; 27(1):33-43. PubMed ID: 18180478
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmaceuticals and medical devices: business practices. End-of-year issue brief.
    Jones TM
    Issue Brief Health Policy Track Serv; 2008 Jan; ():1-32. PubMed ID: 18345554
    [No Abstract]   [Full Text] [Related]  

  • 40. Challenges to a border state pharmacy association.
    Wagenknecht L
    Manag Care; 2004 Mar; 13(3 Suppl):36-7. PubMed ID: 15074170
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.